PER-027-05已完成未知
COMPARATIVE, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, DOUBLE SIMULATED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TELITROMYCIN 25MG / KG SUPPLIED ONCE A DAY FOR 5 OR 10 DAYS DEPENDING ON THE AGE AND HISTORY OF PREVIOUS TREATMENTS VERSUS CEFUROXIMA AXETIL 15 MG / KG SUPPLIED TWICE A DAY FOR 10 DAYS, IN CHILDREN WITH ACUTE MEDIUM OTITIS.
AVENTIS PHARMA S.A.,0 个研究点目标入组 0 人开始时间: 2005年6月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1) Subjects greater than or equal to 6 months and <59 months of age with AOM.
- •2) A sudden and recent attack with signs and symptoms of AOM.
- •3) The presence of LOM in the otoscopy indicated by a protruding tympanic membrane.
- •4) A tympanometry that presents the following results: A type B curve or positive pressure peak curves consistent with the presence of LOM.
- •5) Otalgia or that the patient is pulling or touching the ear in the last 24 hours, that interfere with, or avoid normal activities or sleep.
- •6) At least one of the following non-specific clinical findings for AOM: fever, vomiting, diarrhea, anorexia, sleep disturbances, or irritability.
- •7) Tympanocentesis executed according to the protocol.
- •8) Written informed consent must be obtained at the time of recruitment.
排除标准
- •1) An unclear diagnosis of AOM.
- •2) Otorrea or tube of tympanostosmia present in any of the ears upon entering the study.
- •3) Otitis extema.
- •4) Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis / mucoviscidosis, immobile cilia syndrome, congenital imminence or acquired immunodeficiency syndrome with a <25% CD4 count or requiring prophylaxis for Pneumocystis Jiroveci.
- •5) Known congenital prolonged QT syndrome.
- •6) Uncorrected hypokalemia, hypomagnesemia, bradycardia.
- •7) Myasthenia gravis.
- •8) Known impaired renal function.
- •9) Any medical condition that, in the opinion of the investigator, could interfere with the implementation of the protocol or with the interpretation of the results of the study.
- •10) The subject: a) Is being treated with drugs not allowed by the protocol b) Is currently being treated with sistemic antibacterials or has been treated with systemic antibacterials in the 5 days prior to recruitment c) Has been treated with research drugs inside of the previous 30 days. d) Has been treated with rifampicin, phenytoin, carbamazepine, or St. John´s wort in the last 2 weeks.
- •11) History of hypersensitivity or intolerance to macrolides, penicillins or cephalosporins
- •12) Previous recruitment in this study or previous treatment with telithromycin.
- •13) Children of researcher or sub-investigator, research assistant, pharmacist, study coordinator, or other staff members, or relatives of the people involved in the conduct of the protocol
研究者
相似试验
已完成
不适用
Efficacy and safety of sequential moxifloxacin IV / PO compared to levofloxacin IV plus ceftriaxone IV followed by PO levofloxacin, in the treatment of patients with community-acquired pneumonia.PER-094-03BAYER S.A.,
已完成
不适用
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes-E669 Obesity, unspecifiedObesity, unspecifiedE669PER-053-08sanofi-aventis Recherche & Development,
尚未招募
3 期
Randomized, Multicenter, Multinational, Double-Blind Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Subjects With Stage IV Non-Squamous Non-Small Cell Lung CancerB47 MycetomaMycetomaPER-010-23aboratorio Elea Phoenix S.A.
已完成
不适用
MULTINATIONAL, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY OF ZOLEDRONIC ACID ADMINSTRATED BY INTRAVENOUS VIA IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AFTER A HIP FRACTURE.-S729S729PER-061-02OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
Randomized, multinational, multicentre, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. - CRESCENDOEUCTR2005-002942-20-IESanofi-Synthelabo Recherche17,000